Switzerland's drug surveillance

Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.

Diabetic medicine : a journal of the British Diabetic Association·2011

The effect of GH replacement therapy on different fat compartments: a whole-body magnetic resonance imaging study.

European journal of endocrinology·2010

Effect of growth hormone (GH) on fasting and postprandial metabolism in GH deficiency.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2010

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population.

Diabetic medicine : a journal of the British Diabetic Association·2009

A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.

Diabetes, obesity & metabolism·2009

[Role of complementary medicine in type 1 diabetes mellitus in two Swiss centres].

Praxis·2009

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Lancet (London, England)·2026

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Lancet (London, England)·2026

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Lancet (London, England)·2026

High-dose olanzapine versus standard-dose olanzapine: Effect on all-cause readmission rates in adult psychiatric patients.

The mental health clinician·2026

Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy.

Frontiers in psychiatry·2026

GPR55 and PINK1 as emerging therapeutic targets in Glioma: insights into their modulation by phytochemicals and plant extracts.

Frontiers in pharmacology·2026

Incretin analogues as cardiovascular agents: a state-of-the-art review.

Frontiers in endocrinology·2026

Indobufen-based dual antiplatelet therapy in patients undergoing PCI: a systematic review and meta-analysis.

Frontiers in pharmacology·2026

From Solution to Sublimation: Thermodynamic Evaluation of Iproniazid Multicomponent Crystals for Robust Pharmaceutical Solid Form Development.

Pharmaceutical research·2026

Related Experiment Videos

Switzerland's drug surveillance

Related Concept Videos

Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.

The effect of GH replacement therapy on different fat compartments: a whole-body magnetic resonance imaging study.

Effect of growth hormone (GH) on fasting and postprandial metabolism in GH deficiency.

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population.

A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.

[Role of complementary medicine in type 1 diabetes mellitus in two Swiss centres].

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

High-dose olanzapine versus standard-dose olanzapine: Effect on all-cause readmission rates in adult psychiatric patients.

Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy.

GPR55 and PINK1 as emerging therapeutic targets in Glioma: insights into their modulation by phytochemicals and plant extracts.

Incretin analogues as cardiovascular agents: a state-of-the-art review.

Indobufen-based dual antiplatelet therapy in patients undergoing PCI: a systematic review and meta-analysis.

From Solution to Sublimation: Thermodynamic Evaluation of Iproniazid Multicomponent Crystals for Robust Pharmaceutical Solid Form Development.

Related Experiment Videos

Switzerland's drug surveillance

Related Concept Videos

Related Articles